Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk will slash the list prices for its popular drugs Wegovy and Ozempic by as much as half starting next year
The reductions will take effect next January, and both Ozempic and Wegovy will list for $675 a month.
NVO Stock: Should You Buy The Dip?
Novo Nordisk's stock dropped 16% on February 23rd after clinical trial results indicated that its experimental weight-loss medication, CagriSema, did not perform as well as Eli Lilly's competing drug, Mounjaro. The trial results showed that CagriSema produced lower weight loss outcomes compared to Lilly's GLP-1 therapy, which is a significant setback given that the race for obesity drugs is increasingly favoring a winner-takes-most scenario.
Analyst says he's thrown in the towel on Novo Nordisk after latest setback
Novo Nordisk's study showing a new drug wasn't as good as a rival's led one sell-side analyst to downgrade the stock for the first time in five years.
Novo Nordisk, United Biotechnology obesity drug trial shows 19.7% weight loss
Novo Nordisk said on Tuesday its triple agonist UBT251 of the receptors for GLP-1, GIP and glucagon, jointly developed with United Biotechnology, achieved a statistically significant mean weight loss of up to 19.7% after 24 weeks in a trial.
Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why
The weight-loss drug wars took a fresh turn on Monday.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novo Nordisk's New Weight Loss Shot Loses To Rival Eli Lilly In Clinical Trial—Stock Plummets
Novo Nordisk's experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly's Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo announced Monday, causing its stock to collapse in pre-market trading.
Novo Nordisk: Why Wegovy Growth Beats Wall Street Expectations
Novo Nordisk shares have fallen 16.4% over the past six months. However, I believe Wall Street is still underestimating the prospects of semaglutide at a dose of 25 mg. Even excluding its approval in late December last year, Wegovy generated DKK 79.1 billion in net revenues for Novo Nordisk in 2025, a 35.9% increase year-on-year.
5 Things to Know Before the Stock Market Opens
Stocks are pointing to a lower open amid tariff uncertainty after major indexes posted gains last week; President Donald Trump is imposing new tariffs to replace the ones the Supreme Court struck down on Friday, starting with a 15% global tariff; earnings from Nvidia, Home Depot, Lowe's, Salesforce and other major companies headline a busy week that will also include Trump's State of the Union address; Novo Nordisk shares are slumping after the Ozempic and Wegovy maker disappointed in its latest clinical trial for its next-generation weight-loss drug; and thousands of flights are being delayed or canceled across the East Coast this morning as a blizzard hits the region. Here's what you need to know today.
Novo Nordisk Is Under Pressure - And Trading At A Discount
Novo Nordisk is facing its toughest period in years, yet it remains a 'Strong Buy' and a compelling long-term investment. Novo Nordisk's recent results and 2026 outlook disappointed, with sales and profits under pressure from competition, copycats, and mandated price cuts. Despite near-term headwinds, Novo Nordisk's wide moat, robust pipeline, and historical double-digit growth support confidence in long-term high-single-digit to low-double-digit growth.
Novo Nordisk: The Possible Upside
Weight loss treatments provider Novo Nordisk might have experienced a sharp stock decline after disappointing 2025 results and 2026 outlook, but it has seen an impressive bounce back since. While the expected financial weakness is a real downer, there's a possibility of a sales surprise this year considering the company's recent vigorous actions as well as promising launches. NVO's forward P/E has fallen so low now that further upside looks unmistakable. This is especially true as the company is expected to return to improved financial health from 2027.
Novo Nordisk's Wegovy Weight Loss Shot Approved at Higher Dose in EU
Patients on the higher dose of 7.2 milligrams for about 18 months lost 21% of their body weight on average, a study found.
